|
| 重组人血小板生成素与重组人白细胞介素11治疗血小板减少症疗效与安全性的Meta分析 |
| Meta analysis of Efficacy and Safety of Recombinant Human Thrombopoietin and Recombinant Human Interleukins 11 for the Treatment of Thrombocytopenia |
| |
| DOI： |
| 中文关键词: 重组人血小板生成素 重组人白细胞介素11 血小板减少症 Meta分析 |
| 英文关键词:Recombinant human thrombopoietin Recombinant human interleukins 11 Thrombocytopenia Meta analysis |
| 基金项目: |
|
| 摘要点击次数: 3608 |
| 全文下载次数: 5295 |
| 中文摘要: |
| 摘 要 目的:评价重组人血小板生成素（rhTPO）与重组人白细胞介素11（rhIL-11）治疗血小板减少症的疗效与安全性。方法：检索Cochrane图书馆、PubMed、EMBASE、万方数据库、维普中文数据库、同方中文数据库，纳入重组人血小板生成素与重组人白细胞介素11治疗血小板减少症的所有随机对照试验，采用RevMan 5.0软件对数据进行Meta分析。结果：共纳入10篇文献，合计532例患者。Meta分析结果显示，rhTPO在化疗后血小板恢复至≥1.0×1011·L-1所需时间（MD=-4.39，95%CI：-5.62～-3.16，P＜0.01）、化疗前后血小板升高值（MD=51.36，95%CI：10.23～92.50，P=0.01）、血小板输注比例（OR=0.31，95%CI：0.14~0.67，P＜0.01）等方面均优于rhIL 11，rhIL-11组不良反应发生率高于rhTPO组（OR=0.11，95%CI：0.06~0.23，P＜0.01）。结论：rhTPO在相同时间提升血小板计数，恢复血小板至正常值方面均优于rhIL 11，且不良反应发生率及血小板输注比例更低。 |
| 英文摘要: |
| ABSTRACT Objective: To compare the efficacy and safety of recombinant human thrombopoietin（rhTPO）with recombinant human interleukins 11（rhIL-11） in the treatment of thrombocytopenia. Methods:“Thrombopoietin and rhIL 11” were searched in database which includes Cochrane Library , PubMed , Wanfang data resource, VIP database and CNKI; the censor date was from the time of building database to April 2014. All the calculation and statistical tests were done with RevMan 5.0 software. Results: Totally 10 trials with 532 subjects meeting the criteria were include in this review. All the studies were evaluated strictly according to Jadad standard, and Meta analysis were adopted. A Meta analysis showed that the time needed for platelet recovery after chemotherapy to 1.0×1011·L-1（MD=-4.39，95%CI：-5.62--3.16，P＜0.01），higher platelet values before and after chemotherapy （MD=51.36，95%CI：10.23-92.50，P=0.01），proportion of platelet infusion （OR=0.31，95%CI：0.14-0.67，P＜0.01）of rhTPO were better than that of rhIL-11，proportion of ADR of rhTPO was lower than rhIL-11（OR=0.11，95%CI：0.06-0.23，P＜0.01）. Conclusion: rhTPO was better than rhIL-11 on the same time enhance the platelet count and restore normal, also, it had less adverse reaction and low incidence of platelet infusion rate. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
